Taken together, TRIP13 ubiquitinates and degrades the checkpoint surveillance protein MAD2 via activating Akt signaling pathway, leading to weakened checkpoint surveillance and consequent tumorigenic aneuploidy and drug resistance in MM. This evidence concerns the gene AKT1 and Miyoshi myopathy.